Multi-site analytical evaluation of a chemiluminescent magnetic microparticle immunoassay (CMIA) for sirolimus on the Abbott ARCHITECT analyzer

Clinical Biochemistry

Volumn 42, Issue 15, 2009, Pages 1543-1548

  Schmid, Rainer W ^a   Lotz, Johannes ^b   Schweigert, Rosemarie ^b   Lackner, Karl ^b   Aimo, Giuseppe ^c   Friese, Judith ^d   Rosiere, Thomas ^d   Dickson, Diana ^e   Kenney, Daniel ^e   Maine, Gregory T ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c MOLINETTE HOSPITAL   (Italy)

^d ABBOTT DIAGNOSTICS   (United States)

^e FUJIREBIO INC   (Japan)

Author keywords

CMIA; Immunoassay; Immunosuppression; IMx; LC MS MS; MEIA; Monitoring; Rapamycin; Sirolimus; Transplant

Indexed keywords

DRUG METABOLITE; RAPAMYCIN;

ACCURACY; ANALYZER; ARTICLE; CHEMOLUMINESCENT MAGNETIC MICROPARTICLE IMMUNOASSAY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DETERMINATION; HEMATOCRIT; HUMAN; IMMUNOASSAY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UNITED STATES;

ANTIBODY SPECIFICITY; CHEMILUMINESCENT MEASUREMENTS; CHROMATOGRAPHY, LIQUID; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; MAGNETICS; PARTICLE SIZE; SENSITIVITY AND SPECIFICITY; SIROLIMUS; TANDEM MASS SPECTROMETRY;

EID: 70249140182     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.018     Document Type: Article

References (18)

1. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083-1091
2. Flechner S.M., Kurian S.M., Solez K., et al. De novo kidney transplantation without the use of calcineurin inhibitors preserves renal structure and function at two years. Am. J. Transplant. 4 (2004) 1776-1785
3. Larson T.S., Dean P.G., Stegall M.D., et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am. J. Transplant. 6 (2006) 514-522
4. Christians U., Sattler M., Schiebel H.-M., et al. Isolation of two immunosuppressive metabolites after in vitro metabolism of rapamycin. Drug Metab. Dispos. 20 (1992) 186-191
5. Streit F., Christians U., Schiebel H.-M., et al. Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab. Dispos. 24 (1996) 1272-1278
6. Settler M., Guengerich F.P., Yun C.-H., et al. Cytochrome P450 3A enzymes are responsible for biotransformation of FK-506 and rapamycin in man and rat. Drug Metab. Dispos. 20 (1992) 753-761
7. Napoli K.L., and Kahan B.D. Routine clinical monitoring of sirolimus (rapamycin) whole blood concentrations by HPLC with ultraviolet detection. Clin. Chem. 42 (1996) 1943-1948
8. Holt D.W., Lee T., Jones K., and Johnston A. Validation of an assay for routine monitoring of sirolimus using HPLC with mass spectrometric detection. Clin. Chem. 46 (2000) 1179-1183
9. Wallemaq P.E., Vanbinst R., Asta S., and Cooper D.P. High-throughput liquid chromatography-tandem mass spectrometric analysis of sirolimus in whole blood. Clin. Chem. Lab. Med. 41 (2003) 921-925
10. Wilson D., Johnston F., Holt D., et al. Multicenter evaluation of analytical performance of the microparticle enzyme immunoassay for sirolimus. Clin. Biochem. 39 (2006) 378-386
11. Morris G., Salm P., Taylor P.J., et al. Comparison of the reintroduced MEIA(R) assay with HPLC-MS/MS for the determination of whole-blood sirolimus from transplant recipients. Ther. Drug Monit. 28 (2006) 164-168
12. National Committee for Clinical Laboratory Standards. Evaluation of precision performance of quantitative measurement methods; approved guideline-second edition. NCCLS document EP5-A2 (2004), Wayne, PA, NCCLS
13. Clinical and Laboratory Standards Institute. Interference testing in clinical chemistry; approved guideline second edition. CLSI document EP7-A2 (2005), Clinical and Laboratory Standards Institute, Wayne, PA
14. Passing H., and Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. 21 (1983) 709-720
15. Banaszynski L.A., Liu C.W., and Wandless T.J. Characterization of the FKBP rapamycin FRB ternary complex. J. Am. Chem. Soc. 127 (2005) 4715-4721
16. Yatscoff R.W., Wang P., Chan K., Hicks D., and Zimmerman J.J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther. Drug Monit. 17 (1995) 666-671
17. Annesley T.M., and Clayton L. Simple extraction protocol for analysis of immunosuppressant drugs in whole blood. Clin. Chem. 50 (2004) 1845-1848
18. Holt D.W., McKeown D.A., Lee T.D., Hicks D., Cal P., and Johnston A. The relative proportions of sirolimus metabolites in blood using HPLC with mass-spectrometric detection. Transplant. Proc. 36 (2004) 3223-3225